Asset profile
Diazepam (Libervant)
Small molecule
Evidence outlook
Approved: the acute treatment of intermittent, stereotypic episodes of frequent seizure activity... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
72 competitors in this universe: 9 direct rivals (same mechanism and indication), 3 same-class, 60 same-indication; 43 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Diazepam (Libervant): this drug | Phase 3 | Small molecule | GABA-A receptor | ||
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | ||
| Diastat | Approved | Combination | GABA-A receptor | ||
| Diazepam (Valium) | Approved | Small molecule | GABA-A receptor | ||
| Diazepam (Valtoco) | Approved | Small molecule | GABA-A receptor | ||
| Ganaxolone | Approved | Small molecule | GABA-A receptor | ||
| Midazolam (Nayzilam) | Approved | Small molecule | GABA-A receptor, GABA-A receptor (benzodiazepine site) | ||
| Phenobarbital Sodium Injection (Sezaby) | Approved | Small molecule | GABA-A receptor | ||
| Stiripentol | Approved | Small molecule | GABA-A receptor | ||
| Staccato Alprazolam | Phase 3 | Combination | GABA-A receptor | ||
| KH607 | Phase 3 | Small molecule | GABA-A receptor | ||
| GlyphAllo (allopregnanolone Prodrug) (SPT-300) | Phase 2 | Small molecule | GABA-A receptor | ||
| HS-10353 | Phase 2 | Small molecule | GABA-A receptor | ||
| Brivaracetam | Approved | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | ||
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | ||
| Carbamazepine | Approved | Small molecule | Sodium channels |
…and 57 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
3 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.